Skip to main content
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Kinnate Biopharma Inc. - Common Stock (NQ:KNTE)

N/A UNCHANGED
Last Price Updated: 4:00 PM EDT, Apr 2, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Kinnate Biopharma Inc. - Common Stock

< Previous 1 2 3 4 Next >
10 Analysts Have This to Say About Kinnate Biopharma
 
Via Benzinga
The Latest Analyst Ratings for Kinnate Biopharma
 
Via Benzinga
Kinnate Biopharma Inc. to Participate in Upcoming Investor Conferences
From Kinnate Biopharma
Via GlobeNewswire
Neurofibromatosis Treatment Market Value Expected to Reach $27 Billion By End Of 2029
EQNX::TICKER_START (NASDAQ:KTTA),(NASDAQ:SWTX),(NASDAQ:DAWN),(NASDAQ:VSTM),(NASDAQ:KNTE) EQNX::TICKER_END 
Via FinancialNewsMedia
Expert Ratings for Kinnate Biopharma
 
Via Benzinga
What 4 Analyst Ratings Have To Say About Kinnate Biopharma
 
Via Benzinga
Kinnate Biopharma in Focus: Analyst's Adjusted Price Target and the Potential of KIN-3248
HC Wainwright has lowered the price target for Kinnate Biopharma Inc (NASDAQ: KNTE) to $24 from  
Via Benzinga
Kinnate Biopharma Inc. Reports First Quarter 2023 Financial Results and Recent Corporate Updates
From Kinnate Biopharma
Via GlobeNewswire
7 Stocks With Promising Upside Potential for 100% Returns
If you still want to gamble even during this market environment, these are the stocks with 100% upside potential. 
Via InvestorPlace
Trilogy Metals And 2 Other Penny Stocks Insiders Are Aggressively Buying
The Dow Jones closed lower by over 300 points on Tuesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders... 
Via Benzinga
Kinnate Biopharma Inc. Adds Two New Drug Candidates to Its Growing Targeted Oncology Pipeline and Provides Cash Runway Guidance
From Kinnate Biopharma
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Thursday
  During Thursday's session, 99 companies made new 52-week lows. 
Via Benzinga
First Report of Positive Dose Escalation Data Supports Best-in-Class Profile for Investigational Exarafenib as a Single Agent and in Combination with Binimetinib in BRAF-altered Cancers and NRAS Mutant Melanoma
From Kinnate Biopharma
Via GlobeNewswire
Kinnate Biopharma Inc. Provides Full-Year 2022 Financial Results and Recent Corporate Updates
From Kinnate Biopharma
Via GlobeNewswire
Kinnate Biopharma Inc. to Report First Clinical Data for Its Investigational Pan-RAF Inhibitor, Exarafenib (KIN-2787), in an Oral Presentation at the AACR 2023 Annual Meeting
From Kinnate Biopharma
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Monday
  On Monday, 36 companies set new 52-week lows. 
Via Benzinga
Why Bank Shares Are Trading Lower? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Provention Bio, Inc. (NASDAQ: PRVB) shares jumped 250.8% to $23.50 after Sanofi announced it will acquire the company for $25 per share in cash. 
Via Benzinga
Week In Review: Keymed/Lepu Sign $1.2 Billion Deal Out-Licensing Claudin 18.2 ADC To AstraZeneca
Keymed Bio and Lepu Biopharma out-licensed global rights for their antibody drug conjugate to AstraZeneca in a deal that includes $63 million upfront. Meanwhile, the $937 million agreement between... 
Via Talk Markets
Kinnate Biopharma Inc. Announces Acquisition of Ownership Stake from Series A Investors of the China Joint Venture, Kinnjiu Biopharma Inc., and Initiation of Phase 1 Clinical Trial for Exarafenib (KIN-2787) in People's Republic of China
From Kinnate Biopharma
Via GlobeNewswire
Kinnate Biopharma Inc. Receives Fast Track Designation from the U.S. Food and Drug Administration for KIN-3248, an Investigational Pan-FGFR Inhibitor
From Kinnate Biopharma
Via GlobeNewswire
Kinnate Biopharma Inc. to Participate in the 2023 SVB Securities Global Biopharma Conference
From Kinnate Biopharma
Via GlobeNewswire
Kinnate Biopharma Inc. Adds Global Business and Oncology Expertise to Board of Directors with Appointment of Jill DeSimone as Independent Director
From Kinnate Biopharma
Via GlobeNewswire
Kinnate Biopharma Inc. to Present Trials in Progress Poster for its Pan-FGFR Inhibitor, KIN-3248, at the 2023 ASCO Gastrointestinal Cancers Symposium and ASCO Genitourinary Cancers Symposium
From Kinnate Biopharma
Via GlobeNewswire
Why Inotiv Shares Dipped 57%; Here Are 76 Biggest Movers From Yesterday
Gainers Satixfy Communications Ltd. (NYSE: SATX) jumped 96.4% to settle at $51.70 on Thursday. 
Via Benzinga
Why Elevate Credit Shares Are Trading Higher By Over 71%? Here Are 43 Stocks Moving In Thursday's Mid-Day Session
Gainers Elevate Credit, Inc. (NYSE: ELVT) shares surged 71.2% to $1.8150 after the company agreed to be acquired by Park Cities Asset Management in an all-cash transaction at an implied value of $67... 
Via Benzinga
BrightView Holdings, America's Car-Mart And Some Other Big Stocks Moving Lower On Thursday
U.S. stocks traded lower, with the Nasdaq dropping more than 100 points on Thursday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For November 17, 2022
Upgrades 
Via Benzinga
Walmart To Surge Around 9%? Plus B of A Securities Slashes PT On This Stock By 80%
Credit Suisse raised the price target on Walmart Inc. (NYSE: WMT) from $145 to $160. Credit Suisse analyst Robert Moskow maintained an Outperform rating on the stock. Walmart shares fell 0.5% to... 
Via Benzinga
Kinnate Biopharma Inc. Announces Third Quarter 2022 Financial Results and Recent Corporate Updates
From Kinnate Biopharma
Via GlobeNewswire
Why Norwegian Cruise Line Shares Climbed By Around 12%; Here Are 66 Biggest Movers From Yesterday
Gainers Pintec Technology Holdings Limited (NASDAQ: PT) shares jumped 216.2% to close at $0.9058 on Wednesday. 
Via Benzinga
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.